Managing prostate cancer requires an in-depth understanding of complex systemic pharmacotherapies and their potential drug-drug interactions (DDIs). Whether navigating systemic androgen deprivation therapy (ADT), novel androgen receptor pathway inhibitors (ARPIs), taxane-based chemotherapies, or managing concomitant benign urological conditions like Benign Prostatic Hyperplasia (BPH), evaluating metabolic pathways and receptor dynamics is essential to prevent treatment toxicity,...

Accurate diagnosis of prostate cancer relies on systematic clinical evaluation, biomarkers, advanced multiparametric imaging, and targeted tissue sampling. Because early-stage prostate adenocarcinoma often presents as benign lower urinary tract symptoms (LUTS) or remains entirely asymptomatic, diagnostic missteps can lead to either delayed detection of high-risk disease or unnecessary invasive procedures for benign conditions. Recognizing common...

Prostate cancer is one of the most prevalent malignancies in aging men, characterized by the uncontrolled proliferation of prostatic epithelial cells. Understanding the underlying etiologies, risk factors, clinical signs, and rigorous diagnostic protocols is essential for early detection, accurate risk stratification, and effective long-term management. 1. Understanding Prostate Cancer: Definition and Mechanisms What is Prostate...

Prostate cancer is one of the most common malignancies in aging men, requiring a structured clinical and histological diagnostic evaluation to differentiate it from prevalent benign urological conditions that present with overlapping signs, biological markers, and imaging characteristics. 1. Clinical Overview and Diagnostic Rationale What is Prostate Cancer? Prostate cancer is defined as an invasive...